patients in our cohort (n¼285,70%) had a "low risk" index while 14% (n¼57) had a "high risk" index. Of the remaining 16% of pregnancies with an "intermediate risk" index, 59% were complicated by fetal overgrowth. CONCLUSION: Despite substantial differences between the development and validation cohorts, both the previously published index and a parsimonious 3-variable derivative index proved predictive of fetal overgrowth in pregnancies complicated by diabetes. The index may serve as a tool for targeting the allocation of healthcare resources and treatment individualization, prior to the period of maximal fetal growth velocity in the third trimester.
OBJECTIVE:
To compare neonatal outcomes and assess the costeffectiveness of insulin therapy versus glyburide therapy in women with gestational diabetes in the context of most recent randomized controlled trials. STUDY DESIGN: A cost-effectiveness model using TreeAge software was designed to compare neonatal outcomes following insulin and glyburide management of gestational diabetes. A theoretical cohort of 195,000 women was used with assumed complete medication adherence. Outcomes included treatment method, mode of delivery, shoulder dystocia (SD), permanent brachial plexus injury (BPI), respiratory distress syndrome (RDS), neonatal hypoglycemia, macrosomia (>4000g), and neonatal hyperbilirubinemia. Probabilities were derived from the literature comparing insulin versus glyburide. Costeffectiveness was assessed by comparing cost of assessed outcomes with both neonatal and maternal quality-adjusted life years (QALY), with a cost-effectiveness threshold set at $100,000/QALY.
RESULTS:
Insulin was cost-effective in the management of women with gestational diabetes compared to glyburide. Insulin therapy resulted in 2,295 fewer cases of macrosomia, 386 fewer cases of cesarean deliveries, 12 fewer cases of shoulder dystocia, and 7,235 fewer cases of neonatal hypoglycemia despite an increased cost (Table 1) . There was no difference in cases of permanent brachial plexus injuries. Utilizing insulin therapy resulted in 1,858 more QALYs, with an incremental cost-effectiveness ratio (ICER) of $17,622/QALY. Univariate sensitivity analysis demonstrated that varying the compliance of insulin and glyburide simultaneously did not change the cost-effectiveness (Figure 1) . CONCLUSION: Using our baseline estimates, insulin is cost-effective for the management of gestational diabetes. Providers should take this into account when determining the most appropriate treatment for their patients with A2 GDM. 
